mFlusiva Is Approved. It Won't Be on Shelves Until 2027.
Two Tiers, One Trial
The FDA approved mFlusiva on August 5, 2026, the first messenger RNA flu vaccine cleared for use in the United States, and the trial behind it explains why the agency moved. Moderna enrolled more than 40,000 adults 50 and older across 11 countries and measured how often the new shot prevented flu compared with a licensed standard-dose vaccine already on the market. It won by 26.6 percent, a relative efficacy figure with a confidence interval of 16.7 to 35.4 percent, meaning the true advantage could be smaller but the trial is confident it is real. The mechanism is worth naming plainly: standard flu vaccines are grown inside fertilized chicken eggs, a process rooted in 1940s-era manufacturing that can mutate the virus as it adapts to egg cells and blunt the match to that year's circulating strain. mRNA vaccines skip the egg. They deliver genetic instructions for the flu virus's surface protein directly, built from the actual viral sequence, with no adaptation step to distort it. The approval itself split by age: adults 50 to 64 got full approval on the efficacy data, adults 65 and older got accelerated approval on safety and immune-response data alone, with a confirmatory trial on clinical benefit still to come.
Cleared but Not Stocked
Approval is not the same as a vaccine on a shelf, and flu vaccines run on a manufacturing calendar that closes long before flu season opens. Pharmacies and health systems place their orders for a given fall's flu vaccine supply months ahead, locking in doses from Sanofi, GSK and CSL Seqirus, the three manufacturers who already hold more than 60 percent of the US flu vaccine market. Moderna's approval landed in August, after this year's ordering cycle had closed, so an adult 50 or older asking a pharmacist for mFlusiva this flu season will likely be told the store does not carry it, not because the shot failed but because the contract for it was never written. Jefferies forecasts $750 million in combined US sales of Moderna's flu shot and a future combined COVID-flu vaccine by 2030. Moderna is not chasing this fall's flu season. It is buying a place in next year's contracting cycle, and betting that a combination shot arrives in time to matter.
Adults 65 and older, the group most likely to die of influenza, are covered by an accelerated approval that assumes the confirmatory trial will confirm what the immune data already suggests. If it does, the split closes on its own by next season. If it does not, the age group that needed this shot most will have spent a year covered by accelerated approval, not confirmed benefit.
Sources
- Healio (healio.com)
- NBC News (nbcnews.com)
- CNBC (cnbc.com)
- Yahoo Finance (ts2.tech) (finance.yahoo.com)
- NPR (npr.org)